Early Detection of Brain Metastases from Advanced Breast Cancer through Education and Screening
Inclusion Criteria
- Subjects must have an initial primary diagnosis of high-risk and/or HER-2 positive breast cancer. For purposes of this screening study, high-risk breast cancer at initial diagnosis is defined as:
- Stage IV disease, OR
- HER-2 positive Stage III disease
B. Subjects must be ³18 years old.
C. Subjects must be within 3 to 36 months of first metastases or Stage IV diagnosis or within 12 to 36 months of initial diagnosis of HER-2 positive Stage III disease.
D. Subjects must sign a written informed consent form, approved by the Institutional Review Board (IRB).
Exclusion Criteria
- Subjects with a prior diagnosis of brain metastases.
B. Subjects who are unable to be safely exposed to magnetic resonance imaging (MRI). Most common exclusions include, but are not limited to, pacemakers, implanted defibrillators, neurostimulators, aneurysm clips, cochlear devices, or any other institution contraindications.
C. Women who are known to be pregnant.
D. Unwillingness of subject to give written informed consent.
For more information about the study, please call (773) 250-0400 and select menu option “8” between 8:00 AM & 5:00 PM CST
Michelle Catalano
Clinical Research Coordinator
Chicago Institute of Neurosurgery and Neuroresearch
4501 North Winchester, 4th Floor
Chicago, Illinois 60640
(773) 250-0422 Office
(877) 713-2694 Pager
(773) 250-0497 Fax
mcatalano@cinn.org
http://www.cinn.org